Curis (CRIS) Competitors $1.74 -0.07 (-3.87%) Closing price 04:00 PM EasternExtended Trading$1.72 -0.02 (-1.15%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRIS vs. DOMH, ACHV, FBIO, SABS, BOLT, MTEM, AMGN, GILD, VRTX, and REGNShould you be buying Curis stock or one of its competitors? The main competitors of Curis include Dominari (DOMH), Achieve Life Sciences (ACHV), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN). These companies are all part of the "biotechnology" industry. Curis vs. Its Competitors Dominari Achieve Life Sciences Fortress Biotech SAB Biotherapeutics Bolt Biotherapeutics Molecular Templates Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Dominari (NASDAQ:DOMH) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation. Do analysts rate DOMH or CRIS? Curis has a consensus target price of $17.00, indicating a potential upside of 877.01%. Given Curis' stronger consensus rating and higher probable upside, analysts clearly believe Curis is more favorable than Dominari.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dominari 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Curis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is DOMH or CRIS more profitable? Dominari has a net margin of -167.73% compared to Curis' net margin of -376.08%. Curis' return on equity of 0.00% beat Dominari's return on equity.Company Net Margins Return on Equity Return on Assets Dominari-167.73% -91.67% -77.80% Curis -376.08%N/A -97.14% Do institutionals and insiders believe in DOMH or CRIS? 42.5% of Dominari shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 33.0% of Dominari shares are owned by insiders. Comparatively, 5.7% of Curis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, DOMH or CRIS? Dominari has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, Curis has a beta of 3.6, suggesting that its stock price is 260% more volatile than the S&P 500. Which has higher valuation and earnings, DOMH or CRIS? Dominari has higher revenue and earnings than Curis. Dominari is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDominari$24.89M3.00-$14.70M-$4.50-1.13Curis$10.91M1.67-$43.39M-$6.23-0.28 Does the media refer more to DOMH or CRIS? In the previous week, Curis had 3 more articles in the media than Dominari. MarketBeat recorded 3 mentions for Curis and 0 mentions for Dominari. Curis' average media sentiment score of 0.20 beat Dominari's score of 0.00 indicating that Curis is being referred to more favorably in the news media. Company Overall Sentiment Dominari Neutral Curis Neutral SummaryDominari and Curis tied by winning 8 of the 16 factors compared between the two stocks. Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRIS vs. The Competition Export to ExcelMetricCurisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.94M$2.92B$5.53B$9.03BDividend YieldN/A2.44%5.24%4.07%P/E Ratio-0.2820.3027.1920.03Price / Sales1.67251.54414.39108.98Price / CashN/A41.7026.2128.59Price / Book-2.457.397.925.55Net Income-$43.39M-$55.04M$3.17B$248.49M7 Day Performance-25.00%3.01%2.18%5.37%1 Month Performance-26.58%-0.21%1.25%6.63%1 Year Performance-72.73%4.48%33.90%21.20% Curis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRISCuris2.8625 of 5 stars$1.74-3.9%$17.00+877.0%-71.2%$18.94M$10.91M-0.2860High Trading VolumeDOMHDominari0.356 of 5 stars$5.44-2.0%N/A+180.3%$81.27M$18.15M0.004Positive NewsACHVAchieve Life Sciences1.1336 of 5 stars$2.26+1.3%$14.33+534.2%-51.5%$77.35MN/A-1.6920High Trading VolumeFBIOFortress Biotech2.1005 of 5 stars$1.86+2.2%$21.00+1,029.0%+6.1%$53.82M$57.67M-0.83170SABSSAB Biotherapeutics3.0193 of 5 stars$1.76+3.8%$13.25+655.0%-39.7%$15.70M$1.32M0.00140Gap UpBOLTBolt Biotherapeutics3.4013 of 5 stars$5.77+2.9%$50.00+766.6%-57.7%$10.75M$7.69M-0.1790Positive NewsHigh Trading VolumeMTEMMolecular TemplatesN/AN/AN/AN/A$1K$23.48M0.00260AMGNAmgen4.5073 of 5 stars$279.21+0.8%$307.82+10.2%-4.1%$149.01B$33.42B25.4828,000Positive NewsGILDGilead Sciences4.833 of 5 stars$110.87+0.2%$110.55-0.3%+66.9%$137.67B$28.75B23.3417,600Positive NewsVRTXVertex Pharmaceuticals4.7566 of 5 stars$445.20+0.9%$511.62+14.9%-4.2%$113.32B$11.02B-113.576,100Positive NewsREGNRegeneron Pharmaceuticals4.9482 of 5 stars$525.00+0.8%$813.57+55.0%-47.3%$56.25B$14.20B13.3715,106 Related Companies and Tools Related Companies Dominari Competitors Achieve Life Sciences Competitors Fortress Biotech Competitors SAB Biotherapeutics Competitors Bolt Biotherapeutics Competitors Molecular Templates Competitors Amgen Competitors Gilead Sciences Competitors Vertex Pharmaceuticals Competitors Regeneron Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRIS) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
